Advertisement
The presentation will be webcast live and can be accessed by visiting theinvestor relations section of NeurogesX' website at www.neurogesx.com. Thewebcast will be archived for 15 days.
Advertisement
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused ondeveloping and commercializing novel pain management therapies. Its initialfocus is on chronic peripheral neuropathic pain, including postherpeticneuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) andpainful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio isled by its product candidate NGX-4010, a dermal patch designed to manage painassociated with peripheral neuropathic pain conditions, that the Companybelieves offers significant advantages over other pain therapies. NeurogesX'marketing authorization application (MAA) to the European Medicines Agency(EMEA) was accepted for review in September 2007 and NeurogesX plans to file anew drug application (NDA) with the U.S. Food and Drug Administration (FDA) in2008 for PHN.
NeurogesX' second most advanced product candidate, NGX-1998, is atopically applied, liquid formulation containing a high concentration ofcapsaicin designed to treat pain associated with neuropathic pain conditions.NGX-1998 is currently in a Phase 1 clinical trial. The objective of thedevelopment program is to determine the ability of NGX-1998 to provideprotracted pain relief from a single treatment. As a liquid, NGX-1998 isexpected to be suitable for areas of the skin where dermal patches may bedifficult or impractical to apply, such as the hairline. The goal of the NGX1998 program is to develop a product that has the potential to be used by abroad spectrum of the physician population. NGX-1998 was previously studiedin two Phase 1 studies in healthy volunteers conducted under an exploratoryinvestigational new drug application.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of thePrivate Securities Litigation Reform Act of 1995 (the "Act"). NeurogesXdisclaims any intent or obligation to update these forward-looking statements,and claims the protection of the Safe Harbor for forward-looking statementscontained in the Act. Examples of such statements include, but are not limitedto, the expected timing of regulatory filings with respect to NeurogesX'product candidates, including for NGX-4010 the potential filing of an NDA; thepotential markets for NeurogesX' product candidates and the expected benefitsof NeurogesX' product candidates. Such statements are based on management'scurrent expectations, but actual results may differ materially due to variousrisks and uncertainties, including, but not limited to, NeurogesX' productcandidates may have unexpected adverse side effects or inadequate therapeuticefficacy; positive results in clinical trials may not be sufficient to obtainFDA or European regulatory approval; any regulatory approvals which arereceived may be limited to certain indications; physician or patientreluctance to use NGX-4010, if approved, or the inability of physicians toobtain sufficient reimbursement for such procedures; potential alternativetherapies; maintaining adequate patent or trade secret protection withoutviolating the intellectual property rights of others; and other difficultiesor delays in, clinical development, obtaining regulatory approval, marketac
